EGFR and non-small cell lung carcinoma: The clinical treatment of non-small cell lung cancer (NSCLC) with common EGFR mutations (exon 19 deletion and exon 21 L858R), has made a great breakthrough in these years, especially for targeted EGFR tyrosine kinase inhibitors (TKIs) (1–3).